Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10810413 | 0.61 | RAB9A (0.53) | — | |
| SCHEMBL27262005 | 0.61 | ELANE (0.33) | ELANE | |
| SCHEMBL27338904 | 0.61 | ELANE (0.33) | ELANE | |
| SCHEMBL1768613 | 0.60 | NOS2 (0.37) | ELANE | |
| Dealkylated Diethylpropion SCHEMBL25176894 | 0.60 | TDP1 (0.52) | ELANE | |
| Dealkylated Diethylpropion SCHEMBL1050427 | 0.60 | TDP1 (0.52) | ELANE | |
| Dealkylated Diethylpropion SCHEMBL2236790 | 0.60 | TDP1 (0.52) | ELANE | |
| Dealkylated Diethylpropion SCHEMBL20095234 | 0.60 | TDP1 (0.52) | ELANE | |
| Cathinone SCHEMBL34513 | 0.60 | TDP1 (0.52) | ELANE | |
| SCHEMBL16694617 | 0.58 | ALDH1A1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079756-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | Cara Therapeutics, Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| EP-2064228-A2 | SYNTHETIC PEPTIDE AMIDES | Cara Therapeutics, Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008060552-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-1042359-B1 | KAPPA RECEPTOR OPIOID PEPTIDES | CARA THERAPEUTICS INC (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1042359-A1 | KAPPA RECEPTOR OPIOID PEPTIDES | FERRING B.V. (NL) | 2000-10-11 | — | — | EP | claimed |
| US-5965701-A | SYNTHETIC PEPTIDE AMIDE WITH LONG DURATION OF ACTION AND DOES NOT PENETRATE INTO BRAIN; ANALGESICS WITH REDUCED SIDE EFFECTS; ANTIARTHRITIC AGENTS; TREATMENT OF INCONTINENCE, BLADDER INSTABILITY, DIGESTIVE ILEUS, AUTOIMMUNE DISEASES | FERRING BV (NL) | 1999-10-12 | — | — | US | claimed |
| WO-1999032510-A9 | KAPPA RECEPTOR OPIOID PEPTIDES | FERRING BV (NL) | 1999-09-23 | — | — | WO | claimed |
| WO-1999032510-A1 | KAPPA RECEPTOR OPIOID PEPTIDES | FERRING B.V. (NL) | 1999-07-01 | — | — | WO | claimed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| EP-2040733-A2 | METHOD FOR ELEVATING PROLACTIN IN MAMMALS | Cara Therapeutics, Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2008060552-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007139826-A2 | METHOD FOR ELEVATING PROLACTIN IN MAMMALS | CARA THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | ELANE 3011/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | ELANE 1310/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | ELANE 3011/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | ELANE 4032/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | ELANE 1310/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | ELANE 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.